Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...
Updated results from the TALAPRO-2 trial “support talazoparib plus enzalutamide as a standard-of-care initial treatment option for patients with mCRPC,” according to Neeraj Agarwal, MD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback